HT
FATE icon

Headlands Technologies’s Fate Therapeutics FATE Stock Holding History

Headlands Technologies’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$680K Buy
251,802
+126,094
+100% +$233K 0.07% 341
2026
Q1 		$151K Buy
+125,708
New +$153K 0.02% 633
2025
Q3 		– Sell
-49,556
Closed -$55.5K – 841
2025
Q2 		$55.5K Buy
+49,556
New +$57.6K 0.01% 756
2024
Q3 		– Sell
-28,508
Closed -$93.5K – 1294
2024
Q2 		$93.5K Buy
28,508
+27,976
+5,259% +$122K 0.01% 659
2024
Q1 		$3.9K Buy
+532
New +$3.29K ﹤0.01% 1121

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Headlands Technologies's FATE Position: Q2 2026 in Review

Headlands Technologies increased its Fate Therapeutics (FATE) stake by 100% in Q2 2026, buying an estimated $233K and bringing the position to 251,802 shares worth $680K. The position accounts for 0.07% of the portfolio, ranked #341.

Headlands Technologies first reported a position in FATE in Q1 2024 and has held it in 5 quarters since. 156 funds tracked by Wall St. Rank hold FATE as of Q2 2026.

  • Headlands Technologies held 251,802 shares of Fate Therapeutics worth $680K as of Q2 2026.
  • Headlands Technologies bought 126,094 Fate Therapeutics shares in Q2 2026, an estimated $233K.
  • Fate Therapeutics made up 0.07% of Headlands Technologies's portfolio in Q2 2026, its #341 holding.
  • Headlands Technologies first reported a position in Fate Therapeutics in Q1 2024 and has held it in 5 quarters since.
  • 156 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2026.

Based on Headlands Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.